Treatments for hermansky-pudlak syndrome

Abstract

In certain aspects, the present disclosure relates to methods of treating Hermansky-Pudlak Syndrome (HPS) using a TβRII antagonist. In part, the disclosure provides TβRII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides methods for treating one or more complications associated with HPS, including complications associated with fibrosis and/or the lung (e.g., pulmonary fibrosis, interstitial lung disease (ILD)).

Dependencies are inferred from the claim text.